Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00— vs Q3 2019 Net Income-$302.77K-$302.77KN/M vs Q3 2019 EPS Diluted$0.00$0.00— vs Q3 2019 Operating Income-$302,774N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end